临床肿瘤学杂志

• 综述与讲座 • 上一篇    下一篇

HPIP蛋白与恶性肿瘤关系的研究进展

王倩,欧阳学农,陈雄   

  1. 350025 福州 南京军区福州总院肿瘤内科
  • 收稿日期:2014-09-10 修回日期:2014-11-26 出版日期:2015-01-31 发布日期:2015-01-31

Progress of the relationship between HPIP and cancer

WANG Qian, OUYANG Xuenong, CHEN Xiong.   

  1. Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, China
  • Received:2014-09-10 Revised:2014-11-26 Online:2015-01-31 Published:2015-01-31

摘要: 随着肿瘤分子生物学的飞速发展,分子靶向治疗已成为肿瘤治疗方法 中最具前景的研究领域,分子靶点的研究也早已成为医学界关注的热点。人造血相关的PBX相互作用蛋白质(HPIP)是一种新型的支架蛋白。近年来根据相关文献报道,HPIP与肿瘤生的长、增殖和转移密切相关,有可能成为肿瘤治疗的新靶点。本文总结了HPIP在恶性肿瘤发展中的作用及其相关机制的研究进展。

Abstract: With the rapid development of tumor molecular biology, molecular targeted therapy has become the most promising treatment of cancer and the study of molecular targets has been to be a hot topic for a long time. Remarkably, hematopoietic Pbx-interaction protein (HPIP), a microtubule-binding protein, is a novel scaffolding protein. To date, according to the relevant literature, HPIP is closely associated with tumor growth, proliferation and metastasis. HPIP may be a new target for cancer therapy in the future. We review a representative set of resent studies and summarizes the progress of mechanisms and significance of HPIP in the development of malignant tumors.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!